-DOCSTART- -X- O
The -X- _ O
envelope -X- _ B-Patient
( -X- _ I-Patient
E -X- _ I-Patient
) -X- _ I-Patient
protein -X- _ I-Patient
from -X- _ O
coronaviruses -X- _ O
is -X- _ O
a -X- _ O
small -X- _ O
polypeptide -X- _ O
that -X- _ O
contains -X- _ O
at -X- _ O
least -X- _ O
one -X- _ O
α- -X- _ O
helical -X- _ O
transmembrane -X- _ O
domain. -X- _ O
Absence -X- _ B-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
inactivation -X- _ I-Intervention
, -X- _ O
of -X- _ O
E -X- _ B-Patient
protein -X- _ I-Patient
results -X- _ O
in -X- _ O
attenuated -X- _ O
viruses -X- _ O
, -X- _ O
due -X- _ O
to -X- _ O
alterations -X- _ O
in -X- _ O
either -X- _ O
virion -X- _ O
morphology -X- _ O
or -X- _ O
tropism. -X- _ O
Apart -X- _ O
from -X- _ O
its -X- _ O
morphogenetic -X- _ O
properties -X- _ O
, -X- _ O
protein -X- _ B-Patient
E -X- _ I-Patient
has -X- _ O
been -X- _ O
reported -X- _ O
to -X- _ O
have -X- _ O
membrane -X- _ O
permeabilizing -X- _ O
activity. -X- _ O
Further -X- _ O
, -X- _ O
the -X- _ O
drug -X- _ B-Intervention
hexamethylene -X- _ I-Intervention
amiloride -X- _ I-Intervention
( -X- _ I-Intervention
HMA -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
but -X- _ O
not -X- _ O
amiloride -X- _ B-Comparison
, -X- _ O
inhibited -X- _ B-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
ion -X- _ I-Outcome
channel -X- _ I-Outcome
activity -X- _ I-Outcome
of -X- _ I-Outcome
some -X- _ I-Outcome
synthetic -X- _ I-Outcome
coronavirus -X- _ I-Outcome
E -X- _ I-Outcome
proteins -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
also -X- _ I-Outcome
viral -X- _ I-Outcome
replication. -X- _ I-Outcome
We -X- _ O
have -X- _ O
previously -X- _ O
shown -X- _ O
for -X- _ O
the -X- _ O
coronavirus -X- _ O
species -X- _ O
responsible -X- _ O
for -X- _ O
severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS-CoV -X- _ O
) -X- _ O
that -X- _ O
the -X- _ O
transmembrane -X- _ B-Patient
domain -X- _ I-Patient
of -X- _ I-Patient
E -X- _ I-Patient
protein -X- _ I-Patient
( -X- _ I-Patient
ETM -X- _ I-Patient
) -X- _ I-Patient
forms -X- _ O
pentameric -X- _ O
α-helical -X- _ O
bundles -X- _ O
that -X- _ O
are -X- _ O
likely -X- _ O
responsible -X- _ O
for -X- _ O
the -X- _ O
observed -X- _ O
channel -X- _ O
activity. -X- _ O
Herein -X- _ O
, -X- _ O
using -X- _ O
solution -X- _ O
NMR -X- _ O
in -X- _ O
dodecylphosphatidylcholine -X- _ O
micelles -X- _ O
and -X- _ O
energy -X- _ O
minimization -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
obtained -X- _ O
a -X- _ O
model -X- _ O
of -X- _ O
this -X- _ O
channel -X- _ O
which -X- _ O
features -X- _ O
regular -X- _ O
α-helices -X- _ O
that -X- _ O
form -X- _ O
a -X- _ O
pentameric -X- _ O
left-handed -X- _ O
parallel -X- _ O
bundle. -X- _ O
The -X- _ O
drug -X- _ B-Intervention
HMA -X- _ I-Intervention
was -X- _ O
found -X- _ O
to -X- _ O
bind -X- _ O
inside -X- _ O
the -X- _ O
lumen -X- _ O
of -X- _ O
the -X- _ O
channel -X- _ O
, -X- _ O
at -X- _ O
both -X- _ O
the -X- _ O
C-terminal -X- _ O
and -X- _ O
the -X- _ O
N- -X- _ O
terminal -X- _ O
openings -X- _ O
, -X- _ O
and -X- _ O
, -X- _ O
in -X- _ O
contrast -X- _ O
to -X- _ O
amiloride -X- _ B-Comparison
, -X- _ O
induced -X- _ O
additional -X- _ O
chemical -X- _ O
shifts -X- _ O
in -X- _ O
ETM. -X- _ O
Full -X- _ O
length -X- _ O
SARS-CoV -X- _ O
E -X- _ O
displayed -X- _ O
channel -X- _ O
activity -X- _ O
when -X- _ O
transiently -X- _ O
expressed -X- _ O
in -X- _ O
human -X- _ O
embryonic -X- _ O
kidney -X- _ O
293 -X- _ O
( -X- _ O
HEK-293 -X- _ O
) -X- _ O
cells -X- _ O
in -X- _ O
a -X- _ O
whole-cell -X- _ O
patch -X- _ O
clamp -X- _ O
set-up. -X- _ O
This -X- _ O
activity -X- _ B-Intervention
was -X- _ I-Intervention
significantly -X- _ I-Intervention
reduced -X- _ I-Intervention
by -X- _ I-Intervention
hexamethylene -X- _ I-Intervention
amiloride -X- _ I-Intervention
( -X- _ I-Intervention
HMA -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
but -X- _ O
not -X- _ O
by -X- _ O
amiloride. -X- _ B-Comparison
The -X- _ O
channel -X- _ O
structure -X- _ O
presented -X- _ O
herein -X- _ O
provides -X- _ O
a -X- _ O
possible -X- _ O
rationale -X- _ O
for -X- _ O
inhibition -X- _ O
, -X- _ O
and -X- _ O
a -X- _ O
platform -X- _ O
for -X- _ O
future -X- _ O
structure- -X- _ O
based -X- _ O
drug -X- _ O
design -X- _ O
of -X- _ O
this -X- _ O
potential -X- _ O
pharmacological -X- _ O
target -X- _ O
. -X- _ O

